Andrew Polovin Sells 8,143 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 8,143 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $480,844.15. Following the completion of the sale, the executive vice president directly owned 99,447 shares of the company’s stock, valued at $5,872,345.35. This trade represents a 7.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Andrew Polovin also recently made the following trade(s):

• On Friday, February 20th, Andrew Polovin sold 10,949 shares of Tempus AI stock. The shares were sold at an average price of $60.31, for a total value of $660,334.19.
• On Monday, November 24th, Andrew Polovin sold 12,874 shares of Tempus AI stock. The stock was sold at an average price of $75.00, for a total value of $965,550.00.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $58.37 on Friday. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The stock’s fifty day simple moving average is $62.35 and its two-hundred day simple moving average is $73.50. Tempus AI, Inc. has a 1-year low of $36.22 and a 1-year high of $104.32. The stock has a market cap of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently bought and sold shares of the company. GC Wealth Management RIA LLC bought a new position in Tempus AI in the 4th quarter valued at $399,267,000. Vanguard Group Inc. increased its holdings in shares of Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares during the period. Voloridge Investment Management LLC raised its position in shares of Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Tempus AI by 312.7% during the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after buying an additional 965,730 shares during the period. Finally, AQR Capital Management LLC bought a new stake in Tempus AI during the second quarter valued at $54,020,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TEM shares. Mizuho started coverage on shares of Tempus AI in a research note on Thursday. They set an “outperform” rating and a $100.00 price target for the company. Robert W. Baird began coverage on Tempus AI in a research report on Tuesday. They issued an “outperform” rating and a $59.00 target price for the company. HC Wainwright dropped their price target on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Needham & Company LLC increased their price target on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. lowered their price objective on Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $85.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.